Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy
Authors:
- Francesco RussanoFRFrancesco Russano
- Luigi Dall’OlmoLDLuigi Dall’Olmo
- Davide BrugnoloDBDavide Brugnolo
- Francesco CallegarinFCFrancesco Callegarin
- Marcodomenico MazzaMMMarcodomenico Mazza
- Paolo Del FiorePFPaolo Del Fiore
- Rocco CaminitiRCRocco Caminiti
- Marco RastrelliMRMarco Rastrelli
- Simone MocellinSimone Mocellin
Open Access
- 13 September 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8156
Abstract
Malignant melanoma presents formidable therapeutic challenges due to optical shielding and free-radical scavenging by endogenous melanin, profound tumor microenvironment hypoxia, and aggressive metastatic dissemination, rendering conventional photodynamic therapy (PDT) clinically immature. This narrative review comprehensively synthesizes literature across PubMed/MEDLINE, Scopus, and Web of Science evaluating photochemical mechanisms, photosensitizing agents, bioengineered drug delivery systems, and adjacent light-triggered strategies. Preclinical evidence demonstrates that third-generation photosensitizers, targeted organic/inorganic nanoparticles, and transdermal dissolving microneedle (MN) arrays effectively bypass the stratum corneum, enhance drug bioavailability, and alleviate hypoxia-mediated treatment resistance. Furthermore, femtosecond two-photon PDT converts melanin into an active energy-transfer mediator, while nanotechnology-driven photoimmunotherapy (PIT) triggers immunogenic cell death (ICD) and systemic CD8+ cytotoxic T-lymphocyte activation to induce abscopal regression of un-irradiated distant metastases. Nevertheless, critical translational bottlenecks persist, including an overwhelming reliance on static two-dimensional (2D) cell cultures, a lack of validated prognostic or predictive biomarkers, and a complete absence of randomized controlled clinical trials. Ultimately, advancing melanoma photomedicine from bench to bedside requires standardized photophysical dosimetry, systematic evaluation in multicellular three-dimensional (3D) tumor spheroids, and prospective clinical trials defining its role in multimodal dermato-oncology.Keywords
Funding Information
- Ministero della Salute
This publication has 78 references indexed in Scilit:
- Harnessing Immunogenic PANoptosis With Iridium(III) Biradical Photosensitizers for Melanoma PhotoimmunotherapyAngewandte Chemie International Edition, 2026
- Aptamer-targeted biomimetic gold nanostar core with mesoporous organosilica layer for NIR-triggered chemo-photothermal therapy and CT imaging of melanomaMaterials Science and Engineering: C, 2026
- Synthesis of RGD-dextran-coated Fe-porphyrin-based Zr-MOF for CT/MR imaging and targeted chemo-photothermal therapy of melanomaCarbohydrate Polymers, 2025
- Nucleolin-targeted doxorubicin and ICG co-loaded theranostic lipopolymersome for photothermal-chemotherapy of melanoma in vitro and in vivoEuropean Journal of Pharmaceutics and Biopharmaceutics, 2024
- Microneedles-mediated calcium-ion-modulated nanoamplifier for potentiating photodynamic therapy via specific-tuning assembly and tumor microenvironment remoldBiomedicine & Pharmacotherapy, 2024
- ICG‐based laser treatments for ophthalmic diseases: Toward their safe and rapid strategyLuminescence, 2023
- A self-monitoring microneedle patch for light-controlled synergistic treatment of melanomaBioactive Materials, 2023
- Cubosomes-assisted transdermal delivery of doxorubicin and indocyanine green for chemo-photothermal combination therapy of melanomaBiomedicine & Pharmacotherapy, 2023
- Glycan targeting nanoparticle for photodynamic immunotherapy of melanomaActa Pharmaceutica Sinica B, 2022
- Intelligent and spatiotemporal drug release based on multifunctional nanoparticle-integrated dissolving microneedle system for synergetic chemo-photothermal therapy to eradicate melanomaActa Biomaterialia, 2021